RRM1 domain of the splicing oncoprotein SRSF1 is required for MEK1-MAPK-ERK activation and cellular transformation

Carcinogenesis

Volumn 34, Issue 11, 2013, Pages 2498-2504

  Shimoni Sebag, Ariel ^a   Lebenthal Loinger, Ilana ^a   Zender, Lars ^b   Karni, Rotem ^a  

^a HEBREW UNIVERSITY   (Israel)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; RNA; RNA RECOGNITION MOTIF 1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CELL TRANSFORMATION; DELETION MUTANT; ENZYME ACTIVATION; ENZYME INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTO ONCOGENE; RNA SPLICING; SERINE AND ARGININE SPLICING FACTOR 1 ONCOGENE; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; TUMOR XENOGRAFT;

AMINO ACID MOTIFS; ANIMALS; BLOTTING, WESTERN; CELL ADHESION; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CELLS, CULTURED; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HEK293 CELLS; HUMANS; LIVER; MICE; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MITOGEN-ACTIVATED PROTEIN KINASES; MUTATION; NUCLEAR PROTEINS; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RIBONUCLEOTIDE REDUCTASES; RNA SPLICING; RNA, MESSENGER; RNA-BINDING PROTEINS; SIGNAL TRANSDUCTION; STEM CELLS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84887009665     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgt247     Document Type: Article

References (52)

1. Venables,J.P. (2004) Aberrant and alternative splicing in cancer. Cancer Res., 64, 7647-7654.
2. Srebrow,A. et al. (2006) The connection between splicing and cancer. J. Cell Sci., 119, 2635-2641.
3. Kim,E. et al. (2008) Insights into the connection between cancer and alternative splicing. Trends Genet., 24, 7-10.
4. Papaemmanuil,E. et al. (2011) Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N. Engl. J. Med., 365, 1384-1395.
5. Quesada,V. et al. (2012) Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nat. Genet., 44, 47-52.
6. Yoshida,K. et al. (2011) Frequent pathway mutations of splicing machinery in myelodysplasia. Nature, 478, 64-69.
7. Cohen-Eliav,M. et al. (2013) The splicing factor SRSF6 is amplified and is an oncoprotein in lung and colon cancers. J. Pathol., 229, 630-639.
8. Karni,R. et al. (2007) The gene encoding the splicing factor SF2/ASF is a proto-oncogene. Nat. Struct. Mol. Biol., 14, 185-193.
9. Golan-Gerstl,R. et al. (2011) Splicing factor hnRNP A2/B1 regulates tumor suppressor gene splicing and is an oncogenic driver in glioblastoma. Cancer Res., 71, 4464-4472.
10. Valcárcel,J. et al. (1996) The SR protein family: pleiotropic functions in pre-mRNA splicing. Trends Biochem. Sci., 21, 296-301.
11. Lin,S. et al. (2007) SR proteins and related factors in alternative splicing. Adv. Exp. Med. Biol., 623, 107-122.
12. Manley,J.L. et al. (1996) SR proteins and splicing control. Genes Dev., 10, 1569-1579.
13. Long,J.C. et al. (2009) The SR protein family of splicing factors: master regulators of gene expression. Biochem. J., 417, 15-27.
14. Black,D.L. (2003) Mechanisms of alternative pre-messenger RNA splicing. Annu. Rev. Biochem., 72, 291-336.
15. Cartegni,L. et al. (2002) Listening to silence and understanding nonsense: exonic mutations that affect splicing. Nat. Rev. Genet., 3, 285-298.
16. Zhang,Z. et al. (2004) Involvement of SR proteins in mRNA surveillance. Mol. Cell, 16, 597-607.
17. Sanford,J.R. et al. (2004) A novel role for shuttling SR proteins in mRNA translation. Genes Dev., 18, 755-768.
18. Cáceres,J.F. et al. (1998) A specific subset of SR proteins shuttles continuously between the nucleus and the cytoplasm. Genes Dev., 12, 55-66.
19. Li,X. et al. (2005) Loss of splicing factor ASF/SF2 induces G2 cell cycle arrest and apoptosis, but inhibits internucleosomal DNA fragmentation. Genes Dev., 19, 2705-2714.
20. Li,X. et al. (2006) Alternative splicing and control of apoptotic DNA fragmentation. Cell Cycle, 5, 1286-1288.
21. Anczuków,O. et al. (2012) The splicing factor SRSF1 regulates apoptosis and proliferation to promote mammary epithelial cell transformation. Nat. Struct. Mol. Biol., 19, 220-228.
22. Ghigna,C. et al. (2005) Cell motility is controlled by SF2/ASF through alternative splicing of the Ron protooncogene. Mol. Cell, 20, 881-890.
23. Mayeda,A. et al. (1992) Regulation of alternative pre-mRNA splicing by hnRNP A1 and splicing factor SF2. Cell, 68, 365-375.
24. Cáceres,J.F. et al. (1997) Role of the modular domains of SR proteins in subnuclear localization and alternative splicing specificity. J. Cell Biol., 138, 225-238.
25. Cáceres,J.F. et al. (1993) Functional analysis of pre-mRNA splicing factor SF2/ASF structural domains. EMBO J., 12, 4715-4726.
26. Mayeda,A. et al. (1999) Substrate specificities of SR proteins in constitutive splicing are determined by their RNA recognition motifs and composite pre-mRNA exonic elements. Mol. Cell. Biol., 19, 1853-1863.
27. Chandler,S.D. et al. (1997) RNA splicing specificity determined by the coordinated action of RNA recognition motifs in SR proteins. Proc. Natl Acad. Sci. USA, 94, 3596-3601.
28. Zender,L. et al. (2006) Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell, 125, 1253-1267.
29. Sinha,R. et al. (2010) Arginine methylation controls the subcellular localization and functions of the oncoprotein splicing factor SF2/ASF. Mol. Cell. Biol., 30, 2762-2774.
30. Sanford,J.R. et al. (2005) Reversible phosphorylation differentially affects nuclear and cytoplasmic functions of splicing factor 2/alternative splicing factor. Proc. Natl Acad. Sci. USA, 102, 15042-15047.
31. Ota,M. et al. (2008) Mammalian Tead proteins regulate cell proliferation and contact inhibition as transcriptional mediators of Hippo signaling. Development, 135, 4059-4069.
32. Ge,K. et al. (1999) Mechanism for elimination of a tumor suppressor: aberrant splicing of a brain-specific exon causes loss of function of Bin1 in melanoma. Proc. Natl Acad. Sci. USA, 96, 9689-9694.
33. Jiang,C.C. et al. (2010) Apoptosis of human melanoma cells induced by inhibition of B-RAFV600E involves preferential splicing of bimS. Cell Death Dis., 1, e69.
34. Guichard,C. et al. (2012) Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nat. Genet., 44, 694-698.
35. Nikolaev,S.I. et al. (2012) Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma. Nat. Genet., 44, 133-139.
36. Huang,W. et al. (1993) Raf-1 forms a stable complex with Mek1 and activates Mek1 by serine phosphorylation. Proc. Natl Acad. Sci. USA, 90, 10947-10951.
37. Zheng,C.F. et al. (1994) Activation of MEK family kinases requires phosphorylation of two conserved Ser/Thr residues. EMBO J., 13, 1123-1131.
38. Cantley,L.C. (2002) The phosphoinositide 3-kinase pathway. Science, 296, 1655-1657.
39. DeSilva,D.R. et al. (1998) Inhibition of mitogen-activated protein kinase kinase blocks T cell proliferation but does not induce or prevent anergy. J. Immunol., 160, 4175-4181.
40. Fregoso,O.I. et al. (2013) Splicing-factor oncoprotein SRSF1 stabilizes p53 via RPL5 and induces cellular senescence. Mol. Cell, 50, 56-66.
41. Huang,Y. et al. (2005) SRprises along a messenger's journey. Mol. Cell, 17, 613-615.
42. Li,X. et al. (2005) Inactivation of the SR protein splicing factor ASF/SF2 results in genomic instability. Cell, 122, 365-378.
43. Wu,H. et al. (2010) A splicing-independent function of SF2/ASF in micro- RNA processing. Mol. Cell, 38, 67-77.
44. Yeakley,J.M. et al. (1999) Phosphorylation regulates in vivo interaction and molecular targeting of serine/arginine-rich pre-mRNA splicing factors. J. Cell Biol., 145, 447-455.
45. Pandit,S. et al. (2013) Genome-wide analysis reveals SR protein cooperation and competition in regulated splicing. Mol. Cell, 50, 223-235.
46. Challen,C. et al. (1992) Infrequent point mutations in codons 12 and 61 of ras oncogenes in human hepatocellular carcinomas. J. Hepatol., 14, 342-346.
47. Palanisamy,N. et al. (2010) Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nat. Med., 16, 793-798.
48. Imielinski,M. et al. (2012) Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell, 150, 1107-1120.
49. Soret,J. et al. (2005) Selective modification of alternative splicing by indole derivatives that target serine-arginine-rich protein splicing factors. Proc. Natl Acad. Sci. USA, 102, 8764-8769.
50. Bakkour,N. et al. (2007) Small-molecule inhibition of HIV pre-mRNA splicing as a novel antiretroviral therapy to overcome drug resistance. PLoS Pathog., 3, 1530-1539.
51. Ghigna,C. et al. (2010) Pro-metastatic splicing of Ron proto-oncogene mRNA can be reversed: therapeutic potential of bifunctional oligonucleotides and indole derivatives. RNA Biol., 7, 495-503.
52. Keriel,A. et al. (2009) Protection against retrovirus pathogenesis by SR protein inhibitors. PLoS One, 4, e4533.